iwCLL 2023 | Cys-ser mutation-driven ibrutinib resistance and alternative BTKi’s under development
In this video, Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, briefly comments on the BTK inhibitors (BTKi’s) in development for patients with chronic lymphocytic leukemia (CLL) who have developed resistance to ibrutinib due to a cys-ser mutation (this occurs in 80% of patients). This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
We will hear at this meeting a lot about alternative BTK inhibitors, such as non-covalent binding BTK inhibitors, which can overcome this mutation as they don’t need exactly the same binding site to still be active. And there are a number of drugs which are quite far in development, such as pirtobrutinib or also nemtabrutinib, but others are following. Besides that, they are still active in those patients carrying these mutations, particularly based so far on the limited data pirtobrutinib and we will see more about nemtabrutinib...
We will hear at this meeting a lot about alternative BTK inhibitors, such as non-covalent binding BTK inhibitors, which can overcome this mutation as they don’t need exactly the same binding site to still be active. And there are a number of drugs which are quite far in development, such as pirtobrutinib or also nemtabrutinib, but others are following. Besides that, they are still active in those patients carrying these mutations, particularly based so far on the limited data pirtobrutinib and we will see more about nemtabrutinib. But they also have a very favorable safety profile.
Read more...
